WEBULL
WebtradeDownload

Does Expanded Tukysa Approval Change The Bull Case For Pfizer (PFE)?

Simply Wall St · 1d ago
  • Pfizer secured expanded FDA approval for TUKYSA in HER2 positive metastatic breast cancer and released extensive infectious disease data across vaccines and treatments, including pneumococcal, COVID 19, Lyme disease, RSV and meningococcal programs.
  • The mix of oncology progress and late stage vaccine results highlights how Pfizer is working to refresh future revenue sources as older drugs face patent expiry and COVID demand normalizes.
  • The next area of focus is how Pfizer's expanded TUKYSA use fits within its broader investment narrative, including pipeline execution and cost discipline.

Scan how Pfizer’s oncology push and vaccine pipeline compare with other potential compounders by lining up its progress against 33 high quality undervalued stocks in similar sectors.

Pfizer Investment Narrative Recap

To own Pfizer today, you need to believe management can replace shrinking COVID sales with oncology, obesity and vaccine franchises while holding margins together through the US$9.7b cost saving program. The key near term swing factor is execution on launched and acquired assets, supported by real world evidence from vaccines and new TUKYSA usage.

The biggest risk remains a squeeze from pricing pressure and patent losses hitting at the same time as heavy R&D and a stretched dividend payout, with margins already weaker than last year. This week’s oncology and IDWeek updates help sentiment but do not remove that earnings quality concern.

The expanded FDA approval for TUKYSA in HER2+ metastatic breast cancer is the announcement that ties most closely to Pfizer’s current catalyst story. It relates directly to the idea that oncology can represent a larger share of total sales over time and supports ongoing investment in targeted therapies and antibody drug conjugates.

For you as a shareholder, this matters because the broader thesis assumes launched and acquired medicines, now described at a US$13b annualized rate, continue gaining traction while COVID revenue moves toward the guided US$4b in 2026. Any setback in TUKYSA adoption or further oncology pipeline disappointments would make that transition more difficult and keep cost cuts under greater scrutiny.

Pfizer's current analyst narrative points to revenue of US$54.3b and earnings of US$9.1b by 2029, alongside an assumed 5.2% yearly decline in revenue and an earnings increase of about US$4.8b from US$4.3b today.

Uncover why Pfizer's fair value indicates a valuation gap that appears consistent with its current price.

NYSE:PFE 1-Year Stock Price Chart
NYSE:PFE 1-Year Stock Price Chart

Exploring Other Perspectives

Some of the most optimistic Pfizer analysts were already banking on obesity and oncology to do far more heavy lifting, with revenue assumptions of about US$56.5b and earnings of US$12.6b by 2029. You can now weigh those upbeat expectations against fresh TUKYSA and IDWeek vaccine data and decide which storyline feels more realistic.

Explore 10 other Pfizer fair value estimates, including one that suggests as much as 149% potential upside from the current price.

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

Looking for more Pfizer sized investment ideas?

If this Pfizer update has sharpened your view on large cap healthcare, the next step is to widen the search and see which other businesses line up with your risk tolerance and return goals using the Simply Wall St Screener.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.